Previous 10 | Next 10 |
Olema Pharmaceuticals ( NASDAQ: OLMA ) said it granted stock options to four new employees to buy a total of 58.3K common shares, effective Oct. 3. The awards were granted under Olema's 2022 Inducement Plan, the company said in an Oct. 4 press release. The stock op...
SAN FRANCISCO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of ...
Gainers: Euro Tech Holdings ( CLWT ) +63% . Invitae ( NVTA ) +59% . Allego ( ALLG ) +54% . Grove Collaborative ( GROV ) +52% . BioAtla ( BCAB ) +40% . The Trade Desk ( TTD ) +37% . Chicken Soup for the Soul Entert...
Olema Pharmaceuticals press release ( NASDAQ: OLMA ): Q2 GAAP EPS of -$0.82 misses by $0.18 . Cash, cash equivalents and marketable securities as of June 30, 2022, were $240.7 million. For further details see: Olema Pharmaceuticals GAAP EPS of -$0.82 misses b...
Received Fast Track designation from U.S. FDA for OP-1250 for the treatment of ER+/HER2- metastatic breast cancer Reported progress across OP-1250 clinical development program, including selection of the recommended Phase 2 dose, initiation of Phase 2 monotherapy enrollment, and...
SAN FRANCISCO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), today announced the advancement of OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), into...
SAN FRANCISCO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women...
Super Micro Computer ( SMCI ) +20% on better-than-expected Q4 prelim results. ToughBuilt Industries ( TBLT ) +16% . MoonLake Immunotherapeutics ( MLTX ) +14% . Visionary Education Technology Holdings ( VEDU ) +12% . Olema Pharmaceuti...
The U.S. Food and Drug Administration (FDA) granted fast track designation to Olema Pharmaceuticals' ( NASDAQ: OLMA ) OP-1250 to treat certain patients with breast cancer. Specifically, the FDA designation for OP-1250 is to treat ER-positive (ER+), human epid...
SAN FRANCISCO, July 21, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to OP-1250, the Company's novel, oral ...
News, Short Squeeze, Breakout and More Instantly...
Olema Pharmaceuticals Inc. Company Name:
OLMA Stock Symbol:
NASDAQ Market:
Olema Pharmaceuticals Inc. Website:
2024-06-13 17:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-04 15:30:03 ET Oppenheimer analyst issues OUTPERFORM recommendation for OLMA on June 4, 2024 02:10PM ET. The previous analyst recommendation was Outperform. OLMA was trading at $14.4 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is one of today's top gainers. The company's shares have moved 17.73% on the day to $13.84. Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's ...